{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:12:02Z","timestamp":1781881922627,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,4]]},"DOI":"10.7759\/cureus.29928","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T06:18:27Z","timestamp":1664950707000},"source":"Crossref","is-referenced-by-count":6,"title":["A Systematic Review of the Risk of Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome"],"prefix":"10.7759","author":[{"given":"Mahrukh","family":"Shahbaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halah","family":"Almatooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Foucambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith D","family":"Esbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Panthangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne R","family":"Cyril Kurupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjumol","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Polycystic ovary syndrome. (2021). Accessed. April 28, 2022: https:\/\/www.womenshealth.gov\/a-z-topics\/polycystic-ovary-syndrome."},{"key":"ref2","unstructured":"Polycystic ovary syndrome (PCOS). (2021). Accessed. April 28, 2022: https:\/\/my.clevelandclinic.org\/health\/diseases\/8316-polycystic-ovary-syndrome-pcos."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S70314","article-title":"Complications and challenges associated with polycystic ovary syndrome: current perspectives","volume":"7","author":"Palomba S","year":"2015","unstructured":"Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015, 7:745-63. 10.2147\/IJWH.S70314","journal-title":"Int J Womens Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000352","article-title":"Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome","volume":"7","author":"Asfari MM","year":"2020","unstructured":"Asfari MM, Sarmini MT, Baidoun F, Al-Khadra Y, Ezzaizi Y, Dasarathy S, McCullough A. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. BMJ Open Gastroenterol. 2020, 7:e000352. 10.1136\/bmjgast-2019-000352","journal-title":"BMJ Open Gastroenterol"},{"key":"ref5","unstructured":"Non-alcoholic fatty liver disease (NAFLD). (2021). Accessed. April 28, 2022: https:\/\/liverfoundation.org\/for-patients\/about-the-liver\/diseases-of-the-liver\/non-alcoholic-fatty-liver-disease\/."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.01.004","article-title":"Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population","volume":"19","author":"Salva-Pastor N","year":"2020","unstructured":"Salva-Pastor N, L\u00f3pez-S\u00e1nchez GN, Ch\u00e1vez-Tapia NC, et al.. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population. Ann Hepatol. 2020, 19:251-7. 10.1016\/j.aohep.2020.01.004","journal-title":"Ann Hepatol"},{"key":"ref7","unstructured":"Non-alcoholic fatty liver disease (NAFLD) and NASH. (2021). Accessed. April 28, 2022: https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14058","article-title":"Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease","volume":"45","author":"Kim JJ","year":"2017","unstructured":"Kim JJ, Kim D, Yim JY, et al.. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017, 45:1403-12. 10.1111\/apt.14058","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dep380","article-title":"Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome","volume":"25","author":"Vassilatou E","year":"2010","unstructured":"Vassilatou E, Lafoyianni S, Vryonidou A, et al.. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod. 2010, 25:212-20. 10.1093\/humrep\/dep380","journal-title":"Hum Reprod"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/uog.10084","article-title":"Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome","volume":"39","author":"Zueff LF","year":"2012","unstructured":"Zueff LF, Martins WP, Vieira CS, Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol. 2012, 39:341-7. 10.1002\/uog.10084","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000242","article-title":"Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center","volume":"64","author":"Taranto DO","year":"2020","unstructured":"Taranto DO, Guimar\u00e3es TC, Couto CA, et al.. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center. Arch Endocrinol Metab. 2020, 64:235-42. 10.20945\/2359-3997000000242","journal-title":"Arch Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1493","article-title":"Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis","volume":"13","author":"Polyzos SA","year":"2014","unstructured":"Polyzos SA, Goulis DG, Kountouras J, et al.. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones (Athens). 2014, 13:519-31. 10.14310\/horm.2002.1493","journal-title":"Hormones (Athens)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_610_18","article-title":"Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome","volume":"151","author":"Chakraborty S","year":"2020","unstructured":"Chakraborty S, Ganie MA, Masoodi I, Jana M, Gupta N, Sofi NY. Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome. Indian J Med Res. 2020, 151:333-41. 10.4103\/ijmr.IJMR_610_18","journal-title":"Indian J Med Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew076","article-title":"Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome","volume":"31","author":"Macut D","year":"2016","unstructured":"Macut D, Tziomalos K, Bo\u017ei\u0107-Anti\u0107 I, et al.. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod. 2016, 31:1347-53. 10.1093\/humrep\/dew076","journal-title":"Hum Reprod"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1382","article-title":"Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance","volume":"97","author":"Jones H","year":"2012","unstructured":"Jones H, Sprung VS, Pugh CJ, et al.. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012, 97:3709-16. 10.1210\/jc.2012-1382","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2013.08.015","article-title":"Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile","volume":"100","author":"Michaliszyn SF","year":"2013","unstructured":"Michaliszyn SF, Lee S, Tfayli H, Arslanian S. Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile. Fertil Steril. 2013, 100:1745-51. 10.1016\/j.fertnstert.2013.08.015","journal-title":"Fertil Steril"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-28032015000200008","article-title":"Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome","volume":"52","author":"Romanowski MD","year":"2015","unstructured":"Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol. 2015, 52:117-23. 10.1590\/S0004-28032015000200008","journal-title":"Arq Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5603\/EP.2014.0058","article-title":"Non-alcoholic fatty liver disease in women with polycystic ovary syndrome - clinical and metabolic aspects and lipoprotein lipase gene polymorphism","volume":"65","author":"Bohdanowicz-Pawlak A","year":"2014","unstructured":"Bohdanowicz-Pawlak A, Lenarcik-Kabza A, Brona A, Kuliczkowska-P\u0142aksej J, \u0141aczma\u0144ski \u0141, Zaleska-Dorobisz U, Milewicz A. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome - clinical and metabolic aspects and lipoprotein lipase gene polymorphism. Endokrynol Pol. 2014, 65:416-21. 10.5603\/EP.2014.0058","journal-title":"Endokrynol Pol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86697-y","article-title":"Non-alcoholic fatty liver disease in polycystic ovary syndrome women","volume":"11","author":"Won YB","year":"2021","unstructured":"Won YB, Seo SK, Yun BH, Cho S, Choi YS, Lee BS. Non-alcoholic fatty liver disease in polycystic ovary syndrome women. Sci Rep. 2021, 11:7085. 10.1038\/s41598-021-86697-y","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i44.7046","article-title":"Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome","volume":"26","author":"Shengir M","year":"2020","unstructured":"Shengir M, Krishnamurthy S, Ghali P, Deschenes M, Wong P, Chen T, Sebastiani G. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. World J Gastroenterol. 2020, 26:7046-60. 10.3748\/wjg.v26.i44.7046","journal-title":"World J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002542","article-title":"Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database","volume":"15","author":"Kumarendran B","year":"2018","unstructured":"Kumarendran B, O'Reilly MW, Manolopoulos KN, et al.. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. PLoS Med. 2018, 15:e1002542. 10.1371\/journal.pmed.1002542","journal-title":"PLoS Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186136","article-title":"Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS","volume":"12","author":"Petta S","year":"2017","unstructured":"Petta S, Ciresi A, Bianco J, et al.. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS One. 2017, 12:e0186136. 10.1371\/journal.pone.0186136","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.10.010","article-title":"Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome","volume":"5","author":"Gambarin-Gelwan M","year":"2007","unstructured":"Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007, 5:496-501. 10.1016\/j.cgh.2006.10.010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1236","article-title":"In overweight\/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls","volume":"8","author":"Economou F","year":"2009","unstructured":"Economou F, Xyrafis X, Livadas S, et al.. In overweight\/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens). 2009, 8:199-206. 10.14310\/horm.2002.1236","journal-title":"Hormones (Athens)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14279","article-title":"Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis","volume":"40","author":"Sarkar M","year":"2020","unstructured":"Sarkar M, Terrault N, Chan W, et al.. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver Int. 2020, 40:355-9. 10.1111\/liv.14279","journal-title":"Liver Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04579.x","article-title":"Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease","volume":"33","author":"Baranova A","year":"2011","unstructured":"Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011, 33:801-14. 10.1111\/j.1365-2036.2011.04579.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s12978-018-0519-2","article-title":"A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis","volume":"15","author":"Wu J","year":"2018","unstructured":"Wu J, Yao XY, Shi RX, Liu SF, Wang XY. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health. 2018, 15:77. 10.1186\/s12978-018-0519-2","journal-title":"Reprod Health"},{"key":"ref29","article-title":"Endocrine and metabolic characteristics in polycystic ovary syndrome","volume":"63","author":"Glintborg D","year":"2016","unstructured":"Glintborg D. Endocrine and metabolic characteristics in polycystic ovary syndrome. Dan Med J. 2016, 63:B5232.","journal-title":"Dan Med J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i26.8351","article-title":"Nonalcoholic fatty liver disease and polycystic ovary syndrome","volume":"20","author":"Vassilatou E","year":"2014","unstructured":"Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol. 2014, 20:8351-63. 10.3748\/wjg.v20.i26.8351","journal-title":"World J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/109932-a-systematic-review-of-the-risk-of-non-alcoholic-fatty-liver-disease-in-women-with-polycystic-ovary-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:12Z","timestamp":1707507672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/109932-a-systematic-review-of-the-risk-of-non-alcoholic-fatty-liver-disease-in-women-with-polycystic-ovary-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.29928","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}